PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Lurasidone - Schizophrenia
PAD Profile : Lurasidone - Schizophrenia
Keywords :
antipsychotics
Brand Names Include :
Latuda
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Not Specified
Important Information :
Transfer of prescribing responsibility (to primary care) may be considered following 3 months initial treatment by the specialist.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
07 December 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends lurasidone as a treatment option in the management of schizophrenia once metabolic syndrome has been identified.
Lurasidone will be initiated by a specialist from Surrey & Borders Partnership NHS Foundation Trust, in line with the lurasidone prescribing pathway (available below).
Transfer of prescribing responsibility (to primary care) may be considered following 3 months initial treatment by the specialist.
Associated BNF Codes
04. Central Nervous System
04.02.01. Antipsychotic drugs